Memorable trades executed with commentaries for this week.
November 4, 2024 to November 8, 2024
For this week an initial investment of $10,000 yielded $99,192 (that's right -- $99,192) in net gains from the companies of our memorable trades. Naturally, the fully documented results as stated may not represent future transactions, but if history is the judge, our G-101-SPM AI algorithm is the the best there is. Indeed, to make BIG MONEY in the stock market you need to be nimble and quick like a MASTERFUL GRASSHOPPER.
PART ONE
11.08.24
$AGX $152.95 bid. SELL/TAKE PROFIT on the remaining 20% of long position. *DAC (dollar average cost includes 100% liquidation to reduce cost to $32.90).
Originally purchase was at $71.92 (9.4.24).
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.08.24
$MNMD $8.615 +1.11. * DAC (dollar average cost) $5.855 (9.10.24).
CHANGE ERXIT TO $11.00 FROM $9.00.
BRIEF: RBC Capital Adjusts Price Target on Mind Medicine to $21 From $20, Maintains Outperform, Speculative Risk Rating.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
1.08.24
$IONQ $23.95 +1.79. SELL/TAKE PROFIT ON 25% OF LONG POSITION. DAC (dollar average cost includes this transaction to reduce the original cost to zero) Last BUY was at 7.39 (4.16.24). Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.08.24
$DJT $29.91 bid. SELL/TAKE PROFIT.
DAC (dollar average cost) $26.63 (11.8.24) https://stocktwits.com/G101SPM/message/591721698
$DJT $26.63 ask. BUY/REVISIT carries SPM 87.32 tag to $30.00 in short term.
11.08.24
$NNE $22.23 bid. DAC (dollar average cost) $20.64 (10.30.24). EXIT $45.00 -- pre Legacy Holding status.
BRIEF: A $2 million investment by NANO Nuclear into LIST’s recently closed, oversubscribed $11.88 million seed round financing.
note: Execution of a strategic agreement between NANO and LIST under which (i) the parties will collaborate on advancing LIST’s cutting-edge enrichment technology as it continues its development and moves towards the regulatory licensing process and (ii) LIST will ultimately provide NANO Nuclear with quantities of uranium hexafluoride (UF6) fuel for use in NANO Nuclear’s advanced portable microreactors in development and for future sale by NANO Nuclear and LIST to third parties.
11.07.24
$SMCI $25.66 bid. SELL/TAKE PROFITS.
* DAC (dollar average cost) $22.78.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.07.24
$SMCI $25.71 bid. DAC (dollar average cost) (3) $22.78 last $20.83 (11.6.24).
SPM's 3-DAY RULE at work - classic example.
11.07.24
$IONQ $21.61 +5.16. DAC (dollar average cost) (4) $9.43 last $7.39 (4.16.24). EXIT $35.00 Legacy Holding.
BRIEF: IonQ Announces Partnership with NKT Photonics for Next-Generation Laser Systems to Power Future Quantum Computers.
11.07.24
$CVKD $17.68 +1.65. DAC (dollar average cost adjusted for 1:15 split with last trade at $11.52 on 09.17.24). EXIT $21.00.
UPDATE: Today filed with SEC quarterly September 30, 2024:
KEY PARTS
^ In early September, Cadrenal leadership met with the U.S. Food and Drug Administration (FDA) to discuss its tecarfarin Phase 3 clinical trial protocol in left ventricular assist device (LVAD) patients and is continuing these discussions.
^Advanced Abbott collaboration discussions regarding Cadrenal's pivotal clinical trial in patients with the Abbott LVAD HeartMate 3, the only LVAD available in the U.S.
^Recent financing transactions totaling $9.8 million increased its cash balance to approximately $11.3 million and strengthened its balance sheet. The net proceeds provide Cadrenal with additional working capital as it advances tecarfarin toward a pivotal Phase 3 trial.
11.07.24
$BIGC $6.725 +1.03. DAC (dollar average cost) $5.295 (11.5.24).
CHANGE EXIT TO $10.00 FROM $8.00 (midterm).
BRIEF: Reports Q3 (Sep) earnings of $0.06 per share, $0.04 better than consensus of $0.02; revenues rose 7.3% year/year to $83.71 mln vs the $83.09 mln.
11.07.24
$AVDX $9.82 bid. DAC (dollar average cost) $7.90. EXIT $21.00 - LH status.
BRIEF: AvidXchange upgraded to Buy from Neutral at Compass Point; tgt raised to $15
11.07.24
NOTICE - PLAN TO RETAIN POSITION ON MAJOR SPM TAG IMPROVEMENT : see prior posting.
$CEVA 25.42 bid. DAC (dollar average cost) $23.935 (11.5.24).
CHANGE EXIT TO $35.00 FROM 28.50.
11.07.24
$EBS $11.07 bid. ** DAC (dollar average cost includes 80% of position * at a profit to reduce cost to zero) $00.00. EXIT $20.00.
UPDATE: Current consensus EPS estimate is -$0.07 on $252.32 million in revenues for the coming quarter and -$1.30 on $1.14 billion in revenues for the current fiscal year.
* Original purchase on REVISIT at $2.21 (11.28.23).
Click SEARCH (magnifying glass) icon on our landing page to review full history from 7.21.23.
11.07.24
$LYFT $17.55 bid. DAC (dollar average cost) $11.27 (9.11.24).
CHANGE EXIT TO $21.00 FROM $16.00.
UPDATE: Reports Q3 (Sep) earnings of $0.29 per share, excluding non-recurring items, $0.10 better than the consensus of $0.19; revenues rose 31.6% year/year to $1.52 bln vs the $1.44 bln.
^Gross Bookings of $4.1 billion was up 16% year-over-year.
^Adjusted EBITDA of $107.3 million compared to $92.0 million in Q3'23.
^Record Active Riders of 24.4 million: up 9% year-over-year.
^^^Q4 Guidance: Guides for Gross Bookings of approximately $4.28 billion to $4.35 billion, up 15% to 17% year-over-year. Adjusted EBITDA of $100 million to $105 million and an Adjusted EBITDA margin (calculated as a percentage of Gross Bookings) of approximately 2.3% to 2.4%
11.06.24
$IONQ $16.72 +2.34. DAC (dollar average cost includes FOUR BUYS last being at $7.39 on 4.16.24) $9.43.
EXIT $35.00 as Legacy Holding status.
UPDATE: EA11.6 confirmed.
IONQ consistent doubling of revenue every year since 2021 highlights strong growth potential, though its stock remains discounted by Wall Street. Short-term catalysts include the November earnings call, where IonQ is expected to announce its first quantum application, and the December launch of its most powerful system in Switzerland. With projections for quantum computing to become a multi-billion-dollar industry, IonQ’s leadership in this space, combined with its technological advancements could see substantial returns heading into 2025.
11.06.24
$EXAS $52.14 ask. COVER SHORT/ TAKE PROFIT last $59.89 (8.26.24)
11.05.24
$DD $84.00 bid. DAC (dollar average cost) (2) $78.705 (5.23.24). EXIT $105.00.
UPDATE: Reports Q3 (Sep) earnings of $1.18 per share, $0.15 better than consensus of $1.03; revenues rose 4.4% year/year to $3.19 bln vs the $3.2 bln.
Co issues mixed guidance for FY24, sees EPS of $3.90 from $3.70 to $3.80 vs. $3.77 ; sees FY24 revs of approx $12.365 bln from $12.40 bln to $12.50 bln vs. $12.44 bln .
11.04.24
$PRAX $71.40 bid. SELL/TAKE PROFIT on 20% position. EXIT $95.00 as Legacy Holding (currently holding a 30% position)
* DAC (dollar average cost includes prior sales of 70% to reduce original cost to $11.25).
note: Original purchase was at $1.55 (9.19.23) subject to 1:15 reverse split ($23.25).
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
11.04.24
$UPWK $13.70 bid. SELL/TAKE PROFITS.
DAC (dollar average cost) (2) $10.39 last $9.27 (8.7.24).
11.04.24
$IRON $59.45 +12.32. SPM 87.95 to $110.00 in midterm. Disc Medicine announces "positive" feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, supporting the regulatory path forward for bitopertin in EPP (47.13) Alignment with the FDA across all proposed study parameters, providing a clear development path to registration. Agreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment period. Potential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpoint. Plan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025.
10.17.24 $IRON $48.55 Watch for this: Plan to provide an update on regulatory interactions for bitopertin in EPP and DISC-0974 in anemia of MF in the second half of 2024. Can cause a 20% SPM tag play.
11.04.23
$SMMT $19.11 bid. DAC (dollar average cost includes various profitable sales to reduce long position to 45% at no cost.) EXIT $40.00.
BRIEF: JMP Securities analyst Reni Benjamin initiates coverage on Summit Therapeutics(SMMT) with a Market Outperform rating and announces Price Target of $32.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
PART TWO
Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate, and culminating with the issuance of an auxiliary SPM tag.
^Follow the daily abstracts: #SPMNOTES #FIRSTLOOK #OPTIONACTION #INSIDERS #DILUTION #SHOWTIME #NOISE #FLASHTRADE #SYMBOLBOX #QUESTIONBOX
^DAC means “dollar average cost” and determines the true cost of the investment position during the cycle of the trade.
IDEA: Devote quality time to understand how to apply the data as a "positional investor."
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior than the other kind. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. These tools do more than process data, G-101 SPM AI generates meaningful content, automate workflows, and unlock insights in ways traditional AI could never achieve.
ARE YOU READY TO MAKE BIG MONEY IN THE STOCK MARKET?
Comments